Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCL19 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCL19 Recombinant Protein (MIP-3 Beta) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 or E. coli expressed options. |
View CCL19 Products |
| Gene Delivery | CCL19 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View CCL19 Products |
| Benchmark Ab | Anti-CCL19 Recombinant Antibody Recombinant positive control for neutralization and binding assays. |
View CCL19 Products |
| Validator | CCL19 siRNA Set For knockdown verification in functional cell-based assays. |
View CCL19 Products |
| Related Target A | CCR7 The primary GPCR receptor for CCL19. Crucial for migration and homing assays. Recommended: Lentivirus for stable cell line generation. |
View CCR7 Products |
| Related Target B | CCL21 Co-ligand for CCR7. Essential for selectivity and competitive binding assays. |
View CCL21 Products |
| Related Target C | IL-7 Often co-expressed with CCL19 in next-generation CAR-T therapies (e.g., 7x19 CAR-T) to enhance solid tumor penetration. |
View IL7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE. |
| GPCR receptor conformation validation | Lentivirus premade particles for CCR7 expression, ensuring native 7-transmembrane conformation for functional assays. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available as positive controls. |
| False Positives | Sequence-specific siRNA pools included to validate target knockdown and assay specificity. |
Live MIP-3 Beta/CCL19 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the MIP-3 Beta/CCL19 axis is experiencing a significant renaissance. While early drug discovery focused primarily on blocking the CCL19/CCR7 pathway to prevent metastasis and alleviate autoimmune disease, modern oncology is leveraging CCL19 as a powerful immunostimulatory agent. The next wave of R&D is heavily focused on synthetic biology and cell therapy, specifically engineering CAR-T cells to secrete CCL19 and IL-7 (7x19 CAR-T) to actively recruit endogenous dendritic cells and T cells into "cold" solid tumors, transforming them into "hot" immunologically active microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Cell Therapy (CAR-T) | Noile-Immune Biotech, Takeda | Solid Tumors (Mesothelioma, Lung Cancer) | Chemotaxis Assay (Need highly pure, active recombinant CCL19 to calibrate migration gradients) |
| Monoclonal Antibody (Antagonist) | Academic Institutes, Biotech Startups | Autoimmune Diseases (RA, Sjögren's Syndrome) | Neutralization Assay (Need sequence-verified CCL19 and CCR7-expressing reporter cells) |
| Bispecific / Fusion Protein | Immunotherapeutics Developers | Lymphoma, Metastatic Cancers | Binding Affinity (Need carrier-free, low-endotoxin CCL19 for high-resolution SPR/BLI analysis) |